United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human Insulin-like Growth Factor-binding Protein 7 (IGFBP-7) ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA
  • Other names:Insulin-like growth factor binding protein-7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBPrP1)
  • Species:Human
Cat. No. Size Price

New RBL015R 96 wells (1 kit) $526,55
PubMed Product Details
Technical Data


Sandwich ELISA


Serum, Urine, Plasma

Sample Requirements

2 µl/well


Shipped on blue ice packs. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

0.125 - 4 ng/ml

Limit of Detection

31 pg/ml

Intra-assay (Within-Run)

n = 8
CV = 5%

Inter-assay (Run-to-Run)

n = 8
CV = 7.5%

Spiking Recovery


Dilution Linearity




It is intended for research use only

The total assay time is less than 3.5 hours

The kit measures IGFBP7

Assay format is 96 wells

Quality Controls are human serum based

Standard is a recombinant protein

Components of the kit are provided ready to use, concentrated or dried

Research topic

Apoptosis, Diabetology - Other Relevant Products, Oncology, Renal disease


IGFBP7 is a member of the insulin superfamily of growth promoting peptides, and is one of the most abundant and common growth factor polypeptides. IGFBPs are a class of secreted proteins that is able to interact with many ligands other than IGFs. Currently, IGFBP-7 has been used as an early diagnosis and prognostic marker for acute renal insufficiency (AKI). IGFBP-7, and TIMP-2 concentrations in the urine of children after receiving injections of contrast medium increased faster than SCr. The combination of IGFBP-7 and TIMP-2 was better than either analyte alone (the specificity was 80.0%, and the sensitivity was 81.2%). Based on the results of two studies, the urine compound of TIMP-2 and IGFBP-7 became US Food and Drug Administration (FDA)-approved biomarker for risk assessment of AKI in ICU patients. IGFBP-7 has also been proposed as a potential prognostic biomarker in heart failure (HF). It provided prognostic information incremental to clinical variables, NT-proBNP, and hsTnT.

Related Products Docs